Skip to content

David Malcom Rodman, Chief Medical Officer at Mineralys Therapeutics, sold MLYS on Jul 13, 2026

Data as of Oct 16

▼ SELL$388K14,058 shares at $27.58David Malcom Rodman Chief Medical OfficerMLYS Mineralys Therapeutics, Inc.
Watch MLYS
Traded
Jul 13, 2026
Disclosed
Jul 15, 2026
Filed
2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

David Malcom Rodman, Chief Medical Officer at Mineralys Therapeutics, sold MLYS on Jul 13, 2026TRADEDDISCLOSED
MLYSSimilar stocks (XLV — its sector index fund), rebased to MLYS's price on the disclosure day
MLYS since disclosure
−25.7%
after the sale
Similar stocks (XLV) since disclosure
+11.6%
XLV — its sector index fund

Change in closing price from Jul 15, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLDavid Malcom Rodman Chief Medical OfficerMLYS Mineralys Therapeutics, Inc.$169Kdisclosed Jul 15 · filed the same day

See every trade on MLYS →